menu

HCC

Podcasts

cardImg

HCC - New Paradigms in Management

04/16/2025

Join Dr. Robert Wong, from Stanford University, Dr. Laura Kulik, from Northwestern, and Dr. Parissa Tabrizian, from Mount Sinai, for an expert discussion on hepatocellular carcinoma (HCC) and the evolving treatment landscape. This high-impact conversation explores how immune checkpoint inhibitors have transformed first-line systemic therapy for HCC, the integration of local regional treatments like Y90 radioembolization, and the growing role of combination strategies, including immunotherapy plus TACE or TKIs. The panel dives into personalized approaches to HCC management, including novel biomarkers, radiomics, and future applications of AI and ctDNA for better patient stratification.

The discussion also highlights expanding liver transplant eligibility through downstaging protocols and the safe use of immunotherapy in pre-transplant settings, as well as the resurgence of living donor liver transplantation. Plus, hear insights into the challenges of post-resection adjuvant therapy and the future of clinical trials in bridging systemic and curative-intent therapies. A must-watch for hepatologists, transplant surgeons, oncologists, and liver disease specialists aiming to stay at the forefront of HCC innovation.
View All Podcasts arrow

Publications

View All Modules arrow
pcbimg

Hepatocellular Carcinoma (HCC) Surveillance Beyond the Guidelines:

07/01/2024

Abstract Library

Unlocking Boundless Knowledge Through Abstracts

View All Modules arrow
alcbimg

Postoperative detection of in clinical cultures and recurrent primary sclerosing cholangitis after liver transplantation: a single-center retrospective cohort study.

06/22/2026

Ichikawa Jun (J);Ito Takashi (T);Sakamoto Katsunori (K);Okumura Shinya (S);Ueda Daisuke (D);Yamashita Tokuyuki (T);Aoyama Hiroki (H);Ataka Ryo (R);Ogiso Satoshi (S);Nagai Kazuyuki (K);Uchida Yoichiro (Y);Ishii Takamichi (T);Hatano Etsuro (E)

alcbimg

Association of metabolic dysfunction-associated steatotic liver disease trajectories with incident liver cancer: a UK Biobank cohort study.

06/22/2026

Kwon Ryuk Jun (RJ);Lim Yohwan (Y)

alcbimg

Hepatitis B core-related antigen as a multifaceted biomarker in chronic hepatitis B: implications for immune activity and hepatocellular carcinoma prediction.

07/01/2026

Tak Kwon Yong (KY);Kim Seok Hwan (SH);Song Myeong Jun (MJ)